معرفی
Privatdozent Dr. Andreas Faust is a leading researcher at the European Institute for Molecular Imaging (EIMI) at the University of Münster, where he heads the Chemical Targeting Lab. His work focuses on developing innovative imaging agents for medical diagnostics, particularly in radiopharmaceutical chemistry and molecular imaging. He maintains strong affiliations with the Department of Nuclear Medicine at the University Hospital Münster and participates in the "Cells in Motion" excellence cluster, contributing to cutting-edge research at the intersection of chemistry, medicine, and imaging technology.
Dr. Faust completed his chemistry studies at the University of Münster, earning his Diploma in 1999, followed by his doctoral degree (Dr. rer. nat.) in 2003 with research on artificial caffeine receptors. His academic journey continued with positions at the Department of Organic Chemistry and the Department of Nuclear Medicine before becoming head of the chemistry group at EIMI in 2011.
Dr. Faust's research centers on organic and medicinal chemistry with specialization in radiopharmaceutical chemistry. His team develops novel tracers for diagnostic molecular imaging using positron emission tomography (PET), single-photon emission computed tomography (SPECT), optical imaging, and photoacoustic imaging. A significant portion of his work focuses on creating specific ligands for the alarmins S100A8/S100A9 and bacteria-specific tracers based on complex carbohydrates or siderophores. His research has important applications in inflammation imaging, infection diagnostics, and cancer theranostics, with emphasis on improving metabolic stability and target specificity of imaging agents.
His publication record demonstrates consistent contributions to molecular imaging, with recent work emphasizing bacteria-specific PET tracers, inflammation imaging targeting S100 proteins, and novel optical imaging probes. The research shows a clear trajectory toward developing clinically applicable imaging agents with improved specificity and metabolic stability, particularly in the areas of infection diagnostics and inflammation monitoring.
- 2017: Best Poster Award at Symposium "Molecular Imaging Agents in Medicine," Groningen
- 2009: Young Investigator Award at Deutscher Röntgenkongress, Berlin
- 2005: Best Scientific Poster Award at 4th Annual Meeting of the Society of Molecular Imaging, Köln
Dr. Faust leads multiple significant research projects, including as Coordinator of a project on immune cell distribution imaging (2019-2024) and as Principal Investigator for CRC-project A03 "Targeting of S100A8/A9 for imaging of inflammatory disorders" and research on vascular graft infections (both 2021-2024). His Chemical Targeting Lab comprises a multidisciplinary team working at the intersection of chemistry, microbiology, and medical imaging, securing substantial funding from the Innovative Medicines Initiative and DFG Collaborative Research Centre.
The Chemical Targeting Lab maintains state-of-the-art facilities for chemical synthesis, radiochemistry, and biological testing. The lab collaborates extensively with microbiologists, clinicians, and imaging specialists to translate basic research into clinical applications. Current research directions include optimizing bacterial imaging probes for clinical diagnostics and developing new inflammation-specific tracers for early disease detection, with particular focus on S100A9-targeted imaging and siderophore-based bacterial detection systems.
